Appropriate Asthma Medicines Nov 10, 2009
Brand names include AccuNeb, Maxair, Proventil, Ventolin and Xopenex. Long-term Relief. (Suite101.com)
Sepracor sued over proposed acquisition Sep 9, 2009
Sepracor makes the sleeping aid Lunesta and the asthma drug Xopenex. Dainippon Sumitomo, based in Osaka, plans to submit its experimental schizophrenia treatment Lurasidone for US regulatory approval in 2010. (Boston Globe)
Dainippon Pharma to buy US co Sep 4, 2009
It will also gain Sepracors insomnia drug Lunesta, asthma drug Xopenex and an experimental epilepsy drug. The deal is the fourth-largest overseas acquisition by a Japanese drugmaker and the second-biggest this year by any Japanese company. (India Times)
Sepracor vows to stay in Mass. Sep 4, 2009
In addition to Lunesta, Sepracor also markets Xopenex and Alvesco for asthma, Brovana for people with chronic lung disease, and the Omnaris nasal spray for people with allergies to dust and pollen. It is seeking US approval to market an epilepsy drug called Stedesa. (Boston Globe)
Dainippon to buy U.S. drug firm Sepracor for $2.6 billion Sep 4, 2009
It will also gain Sepracor's insomnia drug Lunesta, asthma drug Xopenex and an experimental epilepsy drug ... Xopenex is set to face generic competition in 2012. (Yahoo News -- Pharmaceutical Industry News)
Dainippon to Buy Sepracor for $2.7 Billion: Sources Sep 3, 2009
It would also gain Sepracor's insomnia drug Lunesta, asthma drug Xopenex and an experimental epilepsy drug. An announcement of the friendly, negotiated deal was imminent, said one of the sources familiar with the situation, who declined to be named as he was not authorized to speak to the media. (ABC News -- Wire)
Sepracor reportedly a buyout target Sep 3, 2009
But it also has a significant asthma treatment, Xopenex, and is seeking permission to market an epilepsy drug called Stedesa, which it acquired when it bought Oryx Pharmaceuticals last year for $50 million to $70 million ... 9 million, was hurt last year by slowing growth for Lunesta and lower reimbursement rates for Xopenex because of competition from cheaper drugs. (Boston Globe)
Watson to go global with $1.75 billion Arrow buy Jun 20, 2009
Watson also gains exclusive rights to launch a generic version of Sepracor's (SEPR.O) Xopenex asthma drug in 2012, and assumes a patent challenge of AstraZeneca Plc's (AZN.L) Pulmicort asthma medicine, Bisaro said. Overall, he said, the two companies have limited overlap with their product lines. (Yahoo News -- Pharmaceutical Industry News)
How to deal with your child's asthma Jun 19, 2009
What she'll need: A bronchodilator like albuterol or Xopenex (often called a rescue drug). Why: These drugs can instantly open the airways during an attack. (CNN -- Health)
Watson Pharma to Buy Arrow Group for $1.75B Jun 18, 2009
It is also one of the companies challenging the patent on AstraZeneca PLC's asthma drug Pulmicort, and has the right to start selling a generic version of Sepracor Inc.'s respiratory drug Xopenex starting in August 2012. Bisaro said Watson does almost all of its business in the U.S., but Arrow also markets products in Canada, the U.K., France, Germany and Scandinavia. (ABC News -- Wire)
Sepracor chairman unloads $8.7M shares Mar 25, 2009
Earlier in the month, on March 10, the company settled a patent infringement lawsuit against , regarding Sepracor s respiratory drug Xopenex. Under the agreement, Teva can market a generic version of the drug in February of 2013. (Boston Business Journal, MA)
Sepracor, Teva settle patent suit Mar 11, 2009
NEW YORK - said yesterday it will allow to launch generic versions of its respiratory drug Xopenex in 2013 under terms of a patent lawsuit settlement. Teva will be able to launch a licensed generic version of Xopenex inhalation solution on Feb. 17, 2013, and the company will pay Sepracor a royalty on sales ... In 2008, Sepracor reported $441 million in Xopenex revenue. (Boston Globe)
